leisure time -WSS

leisure time

author：comprehensive 2025-09-29 01:37:51 - browse：266

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Lack of darker skin in textbooks, journals harms patients of color

entertainment

WSS

FDA seeking to stop procedures at two unregulated stem cell clinics

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

In Spain, a hospital brews its own CAR

Editas, Vertex strike deal on CRISPR

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

ER docs worry over extreme heat as a 'mass casualty event'

hotspot

leisure time

explore

Psychedelics group wrestles with new pharma identity

US soldier in North Korean custody after crossing DMZ line

In age of alternative facts, a scholarly course on calling out crap

Hospitals owned by private equity see complications spike 25%

Activists slam private health insurers over coverage restrictions

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Virtual care provider acquires bankrupt Pear's prescription apps

focus

Medicare Advantage beneficiaries sue Humana over algorithm use

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

Manchin plays down potential 3rd

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

What we know about the American soldier detained in North Korea

A Theranos scientist

knowledge

hotspot

entertainment

knowledge